185 related articles for article (PubMed ID: 20919746)
1. A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein.
Banappagari S; Ronald S; Satyanarayanajois SD
J Biomol Struct Dyn; 2010 Dec; 28(3):289-308. PubMed ID: 20919746
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.
Kanthala S; Gauthier T; Satyanarayanajois S
Biopolymers; 2014 Jun; 101(6):693-702. PubMed ID: 24222531
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines.
Satyanarayanajois S; Villalba S; Jianchao L; Lin GM
Chem Biol Drug Des; 2009 Sep; 74(3):246-57. PubMed ID: 19703026
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.
Banappagari S; Corti M; Pincus S; Satyanarayanajois S
J Biomol Struct Dyn; 2012; 30(5):594-606. PubMed ID: 22731912
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.
Banappagari S; Ronald S; Satyanarayanajois SD
Medchemcomm; 2011 Jan; 2(8):752-759. PubMed ID: 21887403
[TBL] [Abstract][Full Text] [Related]
6. Design of novel lipidated peptidomimetic conjugates for targeting EGFR heterodimerization in HER2 + cancer.
Naik H; Gauthier T; Singh S; Jois S
Bioorg Med Chem Lett; 2018 Dec; 28(22):3506-3513. PubMed ID: 30314880
[TBL] [Abstract][Full Text] [Related]
7. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
Monsey J; Shen W; Schlesinger P; Bose R
J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
[TBL] [Abstract][Full Text] [Related]
8. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).
Hartman Z; Geldenhuys WJ; Agazie YM
J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694
[TBL] [Abstract][Full Text] [Related]
9. Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3.
Pallerla S; Naik H; Singh S; Gauthier T; Sable R; Jois SD
J Pept Sci; 2018 Feb; 24(2):. PubMed ID: 29436155
[TBL] [Abstract][Full Text] [Related]
10. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
11. Design of peptidomimetics for inhibition of HER2 receptor dimerization by a combination of virtual screening, MD simulations, and QSAR in silico methods.
Jamalan M; Zeinali M; Barzegari Asadabadi E
Chem Biol Drug Des; 2013 Apr; 81(4):455-62. PubMed ID: 23006820
[TBL] [Abstract][Full Text] [Related]
12. [Bacterial synthesis, purification, and solubilization of transmembrane segments of ErbB family members].
Goncharuk MV; Shul'ga AA; Ermoliuk IaS; Tkach EN; Goncharuk SA; Pustovalova IuE; Mineev KS; Bocharov ÉV; Maslennikov IV; Arsen'ev AS; Kirpichnikov MP
Mol Biol (Mosk); 2011; 45(5):892-902. PubMed ID: 22393787
[TBL] [Abstract][Full Text] [Related]
13. Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family.
Arkhipov A; Shan Y; Kim ET; Dror RO; Shaw DE
Elife; 2013 Jul; 2():e00708. PubMed ID: 23878723
[TBL] [Abstract][Full Text] [Related]
14. Disabling receptor ensembles with rationally designed interface peptidomimetics.
Berezov A; Chen J; Liu Q; Zhang HT; Greene MI; Murali R
J Biol Chem; 2002 Aug; 277(31):28330-9. PubMed ID: 12011054
[TBL] [Abstract][Full Text] [Related]
15. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
[TBL] [Abstract][Full Text] [Related]
16. A single ligand is sufficient to activate EGFR dimers.
Liu P; Cleveland TE; Bouyain S; Byrne PO; Longo PA; Leahy DJ
Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10861-6. PubMed ID: 22699492
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain.
Banappagari S; McCall A; Fontenot K; Vicente MG; Gujar A; Satyanarayanajois S
Eur J Med Chem; 2013 Jul; 65():60-9. PubMed ID: 23688700
[TBL] [Abstract][Full Text] [Related]
18. Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells.
Hendriks BS; Orr G; Wells A; Wiley HS; Lauffenburger DA
J Biol Chem; 2005 Feb; 280(7):6157-69. PubMed ID: 15572377
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.
Littlefield P; Liu L; Mysore V; Shan Y; Shaw DE; Jura N
Sci Signal; 2014 Dec; 7(354):ra114. PubMed ID: 25468994
[TBL] [Abstract][Full Text] [Related]
20. Calmodulin binds HER2 and modulates HER2 signaling.
White CD; Li Z; Sacks DB
Biochim Biophys Acta; 2011 May; 1813(5):1074-82. PubMed ID: 21185879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
